Valuation
- Market cap
- 704,862,000
- Revenue TTM
- $5,640,000
- Net income TTM
- $-146,950,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -2,605.50%
- Debt to equity
- 0.00
Trading
- Volume
- 673,300
- Avg volume
- 339,058
- Day's range
- $10.47 – $11.01
- Shares out
- 62,878,000
- Stochastic %K
- 4%
- Beta
- -1.04
- Analysts
- Strong Sell
- Price target
- $40.97
Company profile
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated...
Show more
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 33 1 55 42 78 78
- Website
- https://www.dbv-technologies.com
- Address
- BAtiment IRO, 107 Av. de la REpublique, Châtillon, France
Latest news
No headlines yet.
